Congress funds drug shortage prevention—but hands pharma firms the contracts
H.R. 3955 — RAPID Reserve Act · Filed by Angie Craig (D-MN) · 1 cosponsor · Introduced Jun 12, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a federal program where the Secretary of Health and Human Services awards contracts to pharmaceutical manufacturers, ingredient suppliers, and distributors to maintain 6-month reserves of critical drugs and active pharmaceutical ingredients with vulnerable supply chains. Participating companies receive government contracts to stockpile these reserves domestically or in OECD countries, with preference given to domestic manufacturers, and the government can direct allocation of reserves during public health emergencies or national security threats.
Why we flagged it
The bill establishes a federal contracting mechanism to build and maintain strategic reserves of critical pharmaceuticals and active ingredients, with government direction and allocation authority during emergencies. It is fundamentally a public health supply-chain intervention, not a deregulation or tax measure.
What the text implies
- The bill grants HHS broad discretion to determine which drugs are 'critical' and have 'vulnerable supply chains,' potentially creating a de facto list of government-favored products without explicit congressional approval of each selection.
- Participating manufacturers receive guaranteed government contracts and revenue streams, which may reduce competitive pressure to innovate or lower prices for non-reserve production of the same drugs.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical manufacturers (contract holders); active pharmaceutical ingredient producers; drug wholesalers and distributors (as eligible entities)